Targeting therapy using monoclonal antibody directed against growth factor receptors

H. Jinno, M. Ueda, K. Enomoto, T. Ikeda, M. Kitajima

Research output: Contribution to journalArticle

Abstract

Targeting therapy is expected to be a new effective anti-cancer treatment in near future. Major advances are achieved by considerable effort in this area. Monoclonal antibodies that recognize tumour-associated antigens were conjugated to chemotherapeutic drugs, toxins and radionuclides with various procedures. To apply this new therapy for clinical use, many problems still remain to be clarified. These problems consist of human anti-mouse antibody, antigenic heterogeneity and low tumour uptake. By our experiment, growth factor receptor was an ideal target for targeting therapy and immunoconjugate directed against growth factor receptor showed selective cytotoxicity to cancer cells with expression of growth factor receptor. Moreover, cytotoxic effect was positively correlated with expression level of growth factor receptor.

Original languageEnglish
Pages (from-to)188-193
Number of pages6
JournalHuman cell : official journal of Human Cell Research Society
Volume6
Issue number3
Publication statusPublished - 1993 Sep

Fingerprint

Growth Factor Receptors
Monoclonal Antibodies
Immunoconjugates
Neoplasms
Neoplasm Antigens
Therapeutics
Radioisotopes
Anti-Idiotypic Antibodies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Targeting therapy using monoclonal antibody directed against growth factor receptors. / Jinno, H.; Ueda, M.; Enomoto, K.; Ikeda, T.; Kitajima, M.

In: Human cell : official journal of Human Cell Research Society, Vol. 6, No. 3, 09.1993, p. 188-193.

Research output: Contribution to journalArticle

Jinno, H. ; Ueda, M. ; Enomoto, K. ; Ikeda, T. ; Kitajima, M. / Targeting therapy using monoclonal antibody directed against growth factor receptors. In: Human cell : official journal of Human Cell Research Society. 1993 ; Vol. 6, No. 3. pp. 188-193.
@article{01da5ec873b4400ab18555d5e1c06173,
title = "Targeting therapy using monoclonal antibody directed against growth factor receptors",
abstract = "Targeting therapy is expected to be a new effective anti-cancer treatment in near future. Major advances are achieved by considerable effort in this area. Monoclonal antibodies that recognize tumour-associated antigens were conjugated to chemotherapeutic drugs, toxins and radionuclides with various procedures. To apply this new therapy for clinical use, many problems still remain to be clarified. These problems consist of human anti-mouse antibody, antigenic heterogeneity and low tumour uptake. By our experiment, growth factor receptor was an ideal target for targeting therapy and immunoconjugate directed against growth factor receptor showed selective cytotoxicity to cancer cells with expression of growth factor receptor. Moreover, cytotoxic effect was positively correlated with expression level of growth factor receptor.",
author = "H. Jinno and M. Ueda and K. Enomoto and T. Ikeda and M. Kitajima",
year = "1993",
month = "9",
language = "English",
volume = "6",
pages = "188--193",
journal = "Human Cell",
issn = "0914-7470",
publisher = "Springer Heidelberg",
number = "3",

}

TY - JOUR

T1 - Targeting therapy using monoclonal antibody directed against growth factor receptors

AU - Jinno, H.

AU - Ueda, M.

AU - Enomoto, K.

AU - Ikeda, T.

AU - Kitajima, M.

PY - 1993/9

Y1 - 1993/9

N2 - Targeting therapy is expected to be a new effective anti-cancer treatment in near future. Major advances are achieved by considerable effort in this area. Monoclonal antibodies that recognize tumour-associated antigens were conjugated to chemotherapeutic drugs, toxins and radionuclides with various procedures. To apply this new therapy for clinical use, many problems still remain to be clarified. These problems consist of human anti-mouse antibody, antigenic heterogeneity and low tumour uptake. By our experiment, growth factor receptor was an ideal target for targeting therapy and immunoconjugate directed against growth factor receptor showed selective cytotoxicity to cancer cells with expression of growth factor receptor. Moreover, cytotoxic effect was positively correlated with expression level of growth factor receptor.

AB - Targeting therapy is expected to be a new effective anti-cancer treatment in near future. Major advances are achieved by considerable effort in this area. Monoclonal antibodies that recognize tumour-associated antigens were conjugated to chemotherapeutic drugs, toxins and radionuclides with various procedures. To apply this new therapy for clinical use, many problems still remain to be clarified. These problems consist of human anti-mouse antibody, antigenic heterogeneity and low tumour uptake. By our experiment, growth factor receptor was an ideal target for targeting therapy and immunoconjugate directed against growth factor receptor showed selective cytotoxicity to cancer cells with expression of growth factor receptor. Moreover, cytotoxic effect was positively correlated with expression level of growth factor receptor.

UR - http://www.scopus.com/inward/record.url?scp=0027654943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027654943&partnerID=8YFLogxK

M3 - Article

C2 - 8297815

AN - SCOPUS:0027654943

VL - 6

SP - 188

EP - 193

JO - Human Cell

JF - Human Cell

SN - 0914-7470

IS - 3

ER -